Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. trimmed its position in Edwards Lifesciences Co. (NYSE:EW) by 4.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 214,727 shares of the medical research company’s stock after selling 9,925 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Edwards Lifesciences were worth $14,183,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after buying an additional 806,705 shares during the period. AustralianSuper Pty Ltd increased its position in shares of Edwards Lifesciences by 17.8% during the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares during the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its stake in shares of Edwards Lifesciences by 422.3% in the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company’s stock valued at $29,711,000 after acquiring an additional 364,030 shares during the period. Finally, AIA Group Ltd lifted its holdings in shares of Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after acquiring an additional 358,556 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $70.53 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The firm has a market capitalization of $41.60 billion, a P/E ratio of 10.18, a P/E/G ratio of 4.01 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company’s fifty day moving average price is $68.10 and its 200 day moving average price is $75.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 earnings per share. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of research analyst reports. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Royal Bank of Canada boosted their price target on shares of Edwards Lifesciences from $75.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 27th. Oppenheimer reissued an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Finally, Wells Fargo & Company dropped their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $77.25.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.